Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis - Trial NCT05270460
Access comprehensive clinical trial information for NCT05270460 through Pure Global AI's free database. This Phase 2 trial is sponsored by Processa Pharmaceuticals and is currently Not yet recruiting. The study focuses on Gastroparesis. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Processa Pharmaceuticals
Timeline & Enrollment
Phase 2
Mar 01, 2022
Dec 01, 2022
Primary Outcome
Change in gastric emptying rate from baseline as determined by the AUC of the gastric emptying rate,Change in gastric emptying rate from baseline using t10 and t50 metric for gastric emptying rate,Concentrations of PCS12852 in plasma
Summary
This is a randomized, double-blind, placebo-controlled study that will compare the effect of
 2 different dosage regimens of PCS12852 on gastric emptying time to placebo in both
 idiopathic gastroparesis (IG) and diabetic gastroparesis (DG) patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05270460
Non-Device Trial